Table 3.
Cost-effectiveness analysis (within trial)
| Investigation strategy | Cost (£) mean (95% CI) | Incremental Cost (£) mean (95% CI) | QALY mean (95% CI) | Incremental effect mean (95% CI) | ICER (£) | Probability of each treatment strategy is cost-effective for different threshold values for society’s willingness to pay | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| £0 k (%) | £10 k (%) | £20 k (%) | £30 k (%) | £50 k (%) | ||||||
| Base case, 24 months post randomisation | ||||||||||
| Urethroplasty (n = 46) | 4869 (4123, 5614) | 2148 (689, 3606) | 1.74 (1.61, 1.86) | − 0.01 (− 0.17, 0.14) | 0 | 0 | 1 | 3 | 13 | |
| Urethrotomy (n = 46) | 2721 (1444, 3999) | 1.75 (1.65, 1.85) | Dominant | 100 | 100 | 99 | 97 | 87 | ||
| 24 months post randomisation (rescaled QALY) | ||||||||||
| Urethroplasty (n = 46) | 4869 (4123, 5614) | 2148 (689, 3606) | 1.65 (1.55, 1.76) | − 0.04 (− 0.18, 0.11) | 0 | 0 | 0 | 1 | 4 | |
| Urethrotomy (n = 46) | 2721 (1444, 3999) | 1.69 (1.59, 1.79) | Dominant | 100 | 100 | 100 | 99 | 96 | ||
| 24 months post surgery | ||||||||||
| Urethroplasty (n = 37) | 4963 (3977, 5949) | 1672 (− 65, 3409) | 1.73 (1.54, 1.92) | − 0.04 (− 0.24, 0.16) | 0 | 0 | 4 | 9 | 15 | |
| Urethrotomy (n = 48) | 3291 (1947, 4636) | 1.77 (1.67, 1.87) | Dominant | 100 | 100 | 96 | 91 | 85 | ||
| 24 months post surgery (rescaled QALY) | ||||||||||
| Urethroplasty (n = 37) | 4963 (3977, 5949) | 1672 (− 65, 3409) | 1.42 (1.28, 1.56) | − 0.16 (− 0.31, − 0.01) | 0 | 0 | 0 | 0 | 0 | |
| Urethrotomy (n = 48) | 3291 (1947, 4636) | 1.58 (1.49, 1.67) | Dominant | 100 | 100 | 100 | 100 | 100 | ||
| 24 months post randomisation with imputation | ||||||||||
| Urethroplasty (n = 108) | 4704 (4102, 5305) | 1333 (410, 2256) | 1.73 (1.67, 1.79) | − 0⋅03 (− 0.11, 0.05) | 0 | 0 | 0 | 0 | 1 | |
| Urethrotomy (n = 112) | 3371 (2667, 4074) | 1.76 (1.71, 1.81) | Dominant | 100 | 100 | 100 | 100 | 99 | ||
| 24 months post randomisation with imputation (rescaled QALY) | ||||||||||
| Urethroplasty (n = 108) | 4704 (4102, 5305) | 1333 (410, 2256) | 1.67 (1.62, 1.73) | − 0.05 (− 0.13, 0.02) | 0 | 0 | 0 | 0 | 0 | |
| Urethrotomy (n = 112) | 3371 (2667, 4074) | 1.72 (1.67, 1.77) | Dominant | 100 | 100 | 100 | 100 | 100 | ||
| 24 months post surgery with imputation | ||||||||||
| Urethroplasty (n = 108) | 4704 (4102, 5305) | 1333 (410, 2256) | 1.75 (1.68, 1.82) | − 0.02 (− 0.10, 0.07) | 0 | 0 | 0 | 0 | 3 | |
| Urethrotomy (n = 112) | 3371 (2667, 4074) | 1.76 (1.71, 1.82) | Dominant | 100 | 100 | 100 | 100 | 97 | ||
| 24 months post surgery with imputation (rescaled QALY) | ||||||||||
| Urethroplasty (n = 108) | 4704 (4102, 5305) | 1333 (410, 2256) | 1.67 (1.61, 1.73) | − 0.05 (− 0.12, 0.02) | 0 | 0 | 0 | 0 | 0 | |
| Urethrotomy (n = 112) | 3371 (2667, 4074) | 1.72 (1.67, 1.77) | Dominant | 100 | 100 | 100 | 100 | 100 | ||